Bemcentinib
Bemcentinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target tyrosine-protein kinase receptor UFO.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
12 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 3 | 3 | — | — | — | 4 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | 2 | — | — | — | 2 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | 2 | — | — | — | 2 | |
| Malignant mesothelioma | D000086002 | — | 1 | — | — | — | 1 | ||
| Melanoma | D008545 | 1 | 1 | — | — | — | 1 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 | |
| Adenocarcinoma of lung | D000077192 | — | 1 | — | — | — | 1 | ||
| Triple negative breast neoplasms | D064726 | — | 1 | — | — | — | 1 | ||
| Inflammatory breast neoplasms | D058922 | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | BEMCENTINIB |
| INN | bemcentinib |
| Description | Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase. Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Nc2ccc3c(c2)CC[C@@H](N2CCCC2)CC3)nn1-c1cc2c(nn1)-c1ccccc1CCC2 |
Identifiers
| PDB | — |
| CAS-ID | 1037624-75-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3809489 |
| ChEBI ID | — |
| PubChem CID | 46215462 |
| DrugBank | DB12411 |
| UNII ID | 0ICW2LX8AS (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 290 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more